BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: Currently, PARP inhibitors are effective for TNBC with BRCA1/2 mutation or homologous recombination deficiency (HRD) (Noordermeer and van Attikum, 2019; Geenen et al., 2018; Lee and Djamgoz, 2018).